George Farmer
Stock Analyst at Scotiabank
(2.53)
# 2,241
Out of 5,152 analysts
70
Total ratings
47.37%
Success rate
3.27%
Average return
Main Sectors:
Top Industries:
Stocks Rated by George Farmer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMEA Biomea Fusion | Maintains: Sector Outperform | $30 → $10 | $1.37 | +629.93% | 4 | Aug 6, 2025 | |
| ACLX Arcellx | Maintains: Sector Outperform | $93 → $133 | $114.36 | +16.30% | 4 | Jul 31, 2025 | |
| INMB INmune Bio | Downgrades: Sector Underperform | $23 → $0.6 | $1.27 | -52.57% | 3 | Jul 1, 2025 | |
| URGN UroGen Pharma | Maintains: Sector Outperform | $23 → $47 | $19.61 | +139.67% | 1 | Jun 13, 2025 | |
| SNDX Syndax Pharmaceuticals | Maintains: Sector Perform | $16 → $17 | $21.58 | -21.22% | 4 | May 6, 2025 | |
| TARA Protara Therapeutics | Initiates: Sector Outperform | $12 | $5.82 | +106.19% | 1 | Apr 16, 2025 | |
| TPST Tempest Therapeutics | Downgrades: Sector Perform | $91 → $9 | $2.31 | +289.61% | 4 | Apr 10, 2025 | |
| JANX Janux Therapeutics | Maintains: Sector Perform | $62 → $41 | $13.97 | +193.49% | 4 | Feb 28, 2025 | |
| NAMS NewAmsterdam Pharma Company | Maintains: Sector Outperform | $47 → $52 | $30.14 | +72.53% | 4 | Feb 27, 2025 | |
| BMRN BioMarin Pharmaceutical | Maintains: Sector Perform | $78 → $80 | $60.57 | +32.08% | 8 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $244 → $224 | $188.08 | +19.10% | 4 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $102 | $31.51 | +223.71% | 1 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $18 → $10 | $8.51 | +17.51% | 2 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Sector Outperform | $439 → $715 | $728.11 | -1.80% | 5 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $20 → $23 | $5.70 | +303.51% | 2 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $20 | $0.74 | +2,610.03% | 1 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $70 → $76 | $17.75 | +328.17% | 4 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $13 | $2.59 | +401.93% | 1 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $109 | $53.83 | +102.49% | 3 | Nov 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $94 → $87 | $97.33 | -10.61% | 5 | Nov 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $33 | $3.03 | +989.11% | 1 | Oct 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $1.11 | +3,503.60% | 1 | Jul 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $20 → $27 | $41.28 | -34.59% | 3 | May 6, 2020 |
Biomea Fusion
Aug 6, 2025
Maintains: Sector Outperform
Price Target: $30 → $10
Current: $1.37
Upside: +629.93%
Arcellx
Jul 31, 2025
Maintains: Sector Outperform
Price Target: $93 → $133
Current: $114.36
Upside: +16.30%
INmune Bio
Jul 1, 2025
Downgrades: Sector Underperform
Price Target: $23 → $0.6
Current: $1.27
Upside: -52.57%
UroGen Pharma
Jun 13, 2025
Maintains: Sector Outperform
Price Target: $23 → $47
Current: $19.61
Upside: +139.67%
Syndax Pharmaceuticals
May 6, 2025
Maintains: Sector Perform
Price Target: $16 → $17
Current: $21.58
Upside: -21.22%
Protara Therapeutics
Apr 16, 2025
Initiates: Sector Outperform
Price Target: $12
Current: $5.82
Upside: +106.19%
Tempest Therapeutics
Apr 10, 2025
Downgrades: Sector Perform
Price Target: $91 → $9
Current: $2.31
Upside: +289.61%
Janux Therapeutics
Feb 28, 2025
Maintains: Sector Perform
Price Target: $62 → $41
Current: $13.97
Upside: +193.49%
NewAmsterdam Pharma Company
Feb 27, 2025
Maintains: Sector Outperform
Price Target: $47 → $52
Current: $30.14
Upside: +72.53%
BioMarin Pharmaceutical
Feb 20, 2025
Maintains: Sector Perform
Price Target: $78 → $80
Current: $60.57
Upside: +32.08%
Feb 13, 2025
Maintains: Sector Outperform
Price Target: $244 → $224
Current: $188.08
Upside: +19.10%
Feb 13, 2025
Initiates: Sector Outperform
Price Target: $102
Current: $31.51
Upside: +223.71%
Jan 8, 2025
Maintains: Sector Perform
Price Target: $18 → $10
Current: $8.51
Upside: +17.51%
Nov 5, 2024
Upgrades: Sector Outperform
Price Target: $439 → $715
Current: $728.11
Upside: -1.80%
Oct 18, 2024
Maintains: Sector Outperform
Price Target: $20 → $23
Current: $5.70
Upside: +303.51%
Sep 30, 2024
Initiates: Sector Outperform
Price Target: $20
Current: $0.74
Upside: +2,610.03%
Aug 12, 2024
Maintains: Sector Outperform
Price Target: $70 → $76
Current: $17.75
Upside: +328.17%
Mar 14, 2024
Initiates: Sector Outperform
Price Target: $13
Current: $2.59
Upside: +401.93%
Nov 17, 2020
Downgrades: Market Perform
Price Target: $109
Current: $53.83
Upside: +102.49%
Nov 6, 2020
Maintains: Market Perform
Price Target: $94 → $87
Current: $97.33
Upside: -10.61%
Oct 27, 2020
Initiates: Outperform
Price Target: $33
Current: $3.03
Upside: +989.11%
Jul 20, 2020
Initiates: Outperform
Price Target: $40
Current: $1.11
Upside: +3,503.60%
May 6, 2020
Maintains: Market Perform
Price Target: $20 → $27
Current: $41.28
Upside: -34.59%